On the advanced prostate cancer online support group there have been some questions raised about how we know when drugs like Zytiga and Xtandi have stopped working. Knowing this as soon as possible is important so that you can quickly move on to the next treatment without giving the prostate cancer time to progress and [...]
We have many new drugs that have been recently approved to treat advanced prostate cancer. Two of these drugs are abiraterone (Zytiga) and enzalutamide (Xtandi). These drugs offer new hope to men with advanced prostate cancer after the cancer has become resistant to hormone therapies (called "castration-resistant prostate cancer"). These drugs are a real breakthrough, [...]
Researchers at Johns Hopkins has concluded that metastasis-free survival appeared to independently predictor of overall survival (OS) in men with recurrent prostate cancer who underwent androgen deprivation therapy (ADT) after developing metastases. Men with biochemically recurrent prostate cancer (PSA only) tend to survive for long periods so the FDA gold standard for clinical trial endpoint [...]
The first line of treatment for advanced prostate cancer is Androgen (male hormone) Deprivation Therapy or ADT. Once the PSA progresses (climbs) while still on ADT and with testosterone levels
Dr. Nima Sharifi from the Cleveland Clinic’s Lerner Research Institute has claimed to have identified a genetic mutation in one of the deadliest forms of prostate cancer. His finding, published online today in the journal Cell, shows that there is a mutation that occurs in an enzyme that is present in a drug resistant form [...]